Initial Therapeutics develops small-molecule medicines that inhibit the synthesis of pathogenic proteins associated with diseases caused by protein misfolding and aggregation. This approach targets conditions linked to dysfunctional protein production, providing a potential therapeutic pathway for affected patients.
Funding
$75M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases are caused by the misfolding and aggregation of specific pathogenic proteins. Current treatments often address the symptoms of these diseases but do not target the underlying cause of dysfunctional protein production. This leaves a significant unmet need for therapies that can selectively inhibit the synthesis of these disease-causing proteins at their source.
Solution
Initial Therapeutics is developing a novel approach to treat diseases caused by protein misfolding and aggregation by selectively terminating the synthesis of pathogenic proteins. Their small-molecule medicines are designed to enter the ribosome, the cellular machinery responsible for protein synthesis, and stall the formation of specific disease-causing proteins. By targeting the root cause of these diseases, Initial Therapeutics aims to develop therapies that can halt or reverse disease progression. This innovative approach offers a potential therapeutic pathway for patients suffering from conditions linked to dysfunctional protein production.
Target Audience
The primary target audience includes patients suffering from diseases caused by protein misfolding and aggregation, as well as pharmaceutical companies seeking novel therapeutic approaches for these conditions.
Features
- Small-molecule drugs designed to selectively inhibit the synthesis of pathogenic proteins.
- Targets the ribosome to stall the formation of disease-causing proteins.
- Focuses on diseases caused by protein misfolding and aggregation.